Summary of Key Findings
- Patients taking the highest dose of Lipitor (80 mg) experienced significantly greater improvements in kidney function than patients taking the lowest dose - fifty percent of high dose patients who had kidney dysfunction had normal kidney function at end of study
- An estimated 20 million Americans suffer from chronic kidney disease (CKD), and people with high LDL cholesterol, or "bad" cholesterol are often at an increased risk of developing kidney dysfunction
- Safety of Lipitor 80 mg in the patients in this analysis was similar to that reported for the overall TNT population, with no unexpected safety concerns identified and similar incidences of adverse events between the treatment groups
Patients with coronary heart disease (CHD) and elevated cholesterol who took Lipitor (atorvastatin calcium) experienced improved kidney function, and those improvements were significantly greater among patients taking the highest dose (80 mg). The data, from an analysis of nearly 8,000 patients from the Treating to New Targets (TNT) trial, were presented today at
the 55th Annual Scientific Session of the American College of Cardiology and published online in the Journal of the American College of Cardiology.
An estimated 20 million Americans suffer from chronic kidney disease (CKD).In people with CKD, the kidneys cannot effectively filter the toxins from the blood, which can lead to kidney failure. People with elevated total cholesterol and high LDL cholesterol, or "bad" cholesterol are often at an increased risk of developing kidney dysfunction.
"We anticipated that atorvastatin might provide a protective effect and slow the typical decline in kidney function in this patient population, but we didn't expect to see this level of improvement," said Dr. James Shepherd, TNT steering committee member and clinical academic consultant, Department of Pathological Biochemistry, University of Glasgow Medical School.
The analysis assessed eGFR, or estimated glomerular filtration rate at the beginning and end of the five-year TNT clinical trial. eGFR is used to measure kidney function -- patients with eGFR of less than 60 mL/min are considered to have chronic kidney disease (CKD). eGFR naturally declines with age. Patients in the TNT study did not experience a decline in eGFR -- patients taking Lipitor 10 mg experienced an improvement in kidney function (5.6 percent) and patients taking Lipitor 80 mg experienced a highly significant increase in kidney function (8.5 percent). Fifty percent of patients taking Lipitor 80 mg were no longer classified as having chronic
kidney disease.
- Patients taking the highest dose of Lipitor (80 mg) experienced significantly greater improvements in kidney function than patients taking the lowest dose - fifty percent of high dose patients who had kidney dysfunction had normal kidney function at end of study
- An estimated 20 million Americans suffer from chronic kidney disease (CKD), and people with high LDL cholesterol, or "bad" cholesterol are often at an increased risk of developing kidney dysfunction
- Safety of Lipitor 80 mg in the patients in this analysis was similar to that reported for the overall TNT population, with no unexpected safety concerns identified and similar incidences of adverse events between the treatment groups
Patients with coronary heart disease (CHD) and elevated cholesterol who took Lipitor (atorvastatin calcium) experienced improved kidney function, and those improvements were significantly greater among patients taking the highest dose (80 mg). The data, from an analysis of nearly 8,000 patients from the Treating to New Targets (TNT) trial, were presented today at
the 55th Annual Scientific Session of the American College of Cardiology and published online in the Journal of the American College of Cardiology.
An estimated 20 million Americans suffer from chronic kidney disease (CKD).In people with CKD, the kidneys cannot effectively filter the toxins from the blood, which can lead to kidney failure. People with elevated total cholesterol and high LDL cholesterol, or "bad" cholesterol are often at an increased risk of developing kidney dysfunction.
"We anticipated that atorvastatin might provide a protective effect and slow the typical decline in kidney function in this patient population, but we didn't expect to see this level of improvement," said Dr. James Shepherd, TNT steering committee member and clinical academic consultant, Department of Pathological Biochemistry, University of Glasgow Medical School.
The analysis assessed eGFR, or estimated glomerular filtration rate at the beginning and end of the five-year TNT clinical trial. eGFR is used to measure kidney function -- patients with eGFR of less than 60 mL/min are considered to have chronic kidney disease (CKD). eGFR naturally declines with age. Patients in the TNT study did not experience a decline in eGFR -- patients taking Lipitor 10 mg experienced an improvement in kidney function (5.6 percent) and patients taking Lipitor 80 mg experienced a highly significant increase in kidney function (8.5 percent). Fifty percent of patients taking Lipitor 80 mg were no longer classified as having chronic
kidney disease.
TNT was an investigator-led trial coordinated by an independent steering committee and funded by Pfizer. The study enrolled men and women between 35 and 75 years of age in 14 countries. Demographic characteristics for the patients included in this current analysis were similar to the overall TNT population and were well balanced between treatment groups.
Posts
No comments:
Post a Comment